Outcome of adjuvant imatinib in patients with gastrointestinal stromal tumor: Results of a population-based, matched cohort study. Influence of imatinib interruption and imatinib rechallenge on the ...

Duodenal gastrointestinal stromal tumors (DGISTs) represent a rare subset of mesenchymal neoplasms of the gastrointestinal tract, accounting for approximately 3–5% of all gastrointestinal stromal ...

Most advanced gastrointestinal stromal tumors (GISTs) start with cancer-causing cell changes, or mutations, in specific genes. Changes in proteins called KIT and PDGFRA most commonly cause this cancer ...

Cancer happens when the cells in the body grow and produce out of control. Gastrointestinal stromal tumor (GIST) is a type of cancer that occurs in the gastrointestinal tract, particularly in the ...

The FDA approved Deciphera Pharmaceuticals’ ripretinib (Qinlock), the first drug for fourth-line treatment of advanced gastrointestinal stromal tumors (GISTs). The medication is only indicated for ...

Physicians are underestimating the risk for recurrence in more than a third of patients who have undergone resection of a gastrointestinal stromal tumor (GIST). The result is that many patients do not ...

The location of gastrointestinal stromal tumors in the stomach predicts the mutation profile and drug sensitivity, which can provide direction for treatment decisions and selective genomic testing.

A new technique in which near-infrared hyperspectral imaging (NIR-HSI) is combined with machine learning could be useful for detecting cancers deep within tissue, suggests a research team from Japan.

Association of the genetic variants in the nucleotide excision repair genes XPA and XPC with cisplatin-induced hearing loss in patients with osteosarcoma. Relationship of CUL4A gene underexpression ...

Gastrointestinal stromal tumors (GISTs) are relatively rare form of benign or malignant tumors which occur in the gastrointestinal (GI) tract, especially in the stomach and small intestine. GISTs are ...